Browse Category:

Categories

[Search within category]

Antibodies For The Detection And Treatment Of Oncogenic Ras Driven Cancers

UCSF inventors have developed a technology that allows for the specific targeting of RAS driven tumor cells using antibodies against targets that are differentially expressed on these cells relative to normal cells.

Stroma Biomarkers For Prostate Cancer Diagnosis and Prognosis

Stroma, or connective tissue, consisting namely of fibroblasts and pericytes, are known to interact with nearby tumors and play a major role in cancer progression. Researchers have developed a method of analyzing stroma gene expression in order to more accurately diagnose and assess cancer progression.

Stroma Biomarker For Prostate Cancer Diagnosis and Prognosis

Stroma, or connective tissue, consisting namely of fibroblasts and pericytes, are known to interact with nearby tumors and play a major role in cancer progression. Researchers have developed a method of analyzing stroma gene expression in order to more accurately diagnose and assess cancer progression.

Stroma Biomarkers for Prostate Cancer Diagnosis and Prognosis

Stroma, or connective tissue, consisting namely of fibroblasts and pericytes, are known to interact with nearby tumors and play a major role in cancer progression. Researchers have developed a method of analyzing stroma gene expression in order to more accurately diagnose and assess cancer progression.

A Novel Therapeutic Against HIV Using Human T Cell Immunoglobulin Mucin (TIM-3) Ligands to Modulate Immune Response

Blocking human T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) signaling can restore functionality to defective T cells in HIV-1 infected patients. Additionally, measuring TIM-3 provides clinicians with a novel way of evaluating, staging, and monitoring the progression of HIV infections.

miRNA Therapeutic for Huntington's Disease

Huntington's disease (HD) is a neurodegenerative genetic disorder caused by the mutation of a CAG repeat within the HD gene that causes the accumulation of mHTT species. The biochemical pathways involved in HD are complex and not yet fully uncovered. As a consequence, there are currently no successful disease-modifying therapies for HD. The identification of cellular targets that impact the disease's onset and progression is critical for the development of new treatments. Researchers at UCI and University of Iowa have identified a new target and developed an miRNA therapeutic that reduces accumulation of mHTT in a mouse model of HD.

Synthesis of Lipobactins and Teixobactin Analogues – New Antimicrobial Compositions against Gram-Positive Bacteria

With the discovery of penicillin in the 1940’s, many scientists proclaimed the defeat of infectious diseases which had plagued mankind. However, the remarkable healing power of antibiotics unfortunately invited widespread and indiscriminate use of antibiotics. This misuse and overuse of antibiotics has led to the dramatic rise in antibiotic resistant bacterial strains and increased healthcare costs.

Method to Enrich for Cells Transduced with Chimeric Antigen Receptors

Researchers at UCLA have developed a method to expand chimeric antigen receptor-transduced T cells for use in immunotherapies.

HUMAN ANTIBODY TARGETING HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN

These novel antibodies recognize a cell surface antigen that is highly expressed and exclusive to several types of cancers, including mesothelioma, testicular cancer, endometrial cancer, and subsets of ovarian, pancreatic, and non-small cell lung cancers, thereby holding great potential to facilitate the development of novel cancer therapies. 

NOVEL CONSORTIUM OF BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES

This invention is a rationally designed consortium of bacteria used for the prevention and treatment of inflammatory diseases.

Methods for Disrupting HIV Latency Using Anti-HIV Latency Agents

Researchers at the University of California, Davis have developed methods for reactivating latent viral infection in peripheral blood samples of human immunodeficiency virus (HIV)-infected individuals receiving anti-retroviral therapy and for optimizing the process by including additional reactivation agents.

Deriving Human Naïve Pluripotent Stem Cells by Modifying the Hippo Pathway Using Genetic or Chemical Approaches

This invention identifies a method of generating naïve pluripotent stem cells for subsequent use in research or for regenerative medicine.

Discovery of a Candidate Drug Target for Cancer Therapy

Using primary human materials, researchers at the University of California, Santa Barbara have postulated that a G-protein coupled receptor (GPCR) might be a suitable new target for antibody-drug conjugates (ADCs).

Novel Small Molecule CFTR Activators for the Treatment of Constipation

This invention identifies novel small molecule activators of CFTR (cystic fibrosis transmembrane conductance regulator) that can be developed as effective therapies to treat constipation.

Novel Small Molecule CFTR Activators For the Treatment of Dry Eye

This invention identifies novel small molecule activators of CFTR (cystic fibrosis transmembrane conductance regulator) that can be developed as effective therapies for dry eye disorders.

Use of Embryonic Stem Cell-Specific microRNAs to Safely Promote Induced Pluripotency

Novel use of a family of microRNAs to promote the de-differentiation of somatic cells to induce pluripotent stem cells (iPS cells) for use as therapeutic agents or research tools.

Pyrite Shrink-Wrap Laminate As A Hydroxyl Radical Generator

The invention is a diagnostic technology, as well as a research and development tool. It is a simple, easy to operate, and effective platform for the analysis of pharmaceuticals and biological species. Specifically, this platform generates hydroxyl radicals for oxidative footprinting – a technique commonly employed in protein mapping and analysis. The platform itself is inexpenisve to fabricate, scalable, and requires nothing more than an ordinary pipet to use. In addition, it is highly amenable to scale-up, multiplexing, and automation, and so it holds promise as a high-throughput method for mapping protein structure in support of product development, validation, and regulatory approval in the protein-based therapeutics industry.

Radioactive Soft Tissue Filler For Brachytherapy

The invention is a radioactive gel for treatment of soft tissue cancers. This compliant, biocompatible gel infused with radioactive elements is meant to provide cosmetic tissue restoration as it fills out cavities resulting from tumor removal (e.g. lumpectomies). Once in the cavity, the material delivers precisely dosaged and localized radiation therapy (also known as brachytherapy) to the affected tissues around it.

Modulation of Bioactive Epoxy-Fatty Acid Levels By Phosphodiesterase Inhibitors

Soluble epoxide hydrolase (sEH) is involved in the metabolism of lipid epoxides of arachidonic acid (e.g., cis-epoxyeicosantrienoic acids (“EETs”), linoleic acid, and other lipids (e.g., epoxides of docosahexaenoic acid (“DHA”) or of eicosapentaenoic acid (“EPA”)), some of which are endogenous chemical mediators. Researchers at University of California, Davis have discovered novel sEH inhibitors with high potency and good pharmacokinetics that offer potential to treat multiple indications such as pulmonary diseases, systemic hypertension, and inflammation.

Hemostatic Compositions And Methods Of Use

Wet layered clays used as hemostatic agent to promote blood clotting.

Mesocellular Oxide Foams as Hemostatic Compositions and Methods of Use

Mesocellular foams used as hemostatic agents to facilitate clotting, wound healing, and reduce the risk of infection. It can be provided in combination with antibiotics, ions, or anti-inflammatory agents.

NOVEL OPIOID RECEPTOR AGONIST FOR ANALGESIA WITH REDUCED SIDE EFFECTS

This invention identifies a novel molecule that allows for more effective pain management through selective activation of the µ opioid receptor (MOR) with reduced detrimental side effects. 

Treatment of epilepsy with 5-HT agonists

This technology is a novel method of treating epilepsy disorders with the small molecule clemizole, trazodone and other 5-HT receptor agonists. 

Salmonella-Based Gene Delivery Vectors and their Preparation

Nucleic acid-based gene interference technologies, including ribozymes and small interfering RNAs (siRNAs), represent promising gene-targeting strategies for specific inhibition of mRNA sequences of choice. A fundamental challenge to use nucleic acid-based gene interfering approaches for gene therapy is to deliver the gene interfering agents to appropriate cells in a way that is tissue/cell specific, efficient and safe. Many of the currently used vectors are based on attenuated or modified viruses, or synthetic vectors in which complexes of DNA, proteins, and/or lipids are formed in particles, and tissue-specific vectors have been only partially obtained by using carriers that specifically target certain cell types. As such, efficient and targeted delivery of M1GS sequences to specific cell types and tissues in vivo is central to developing this technology for gene targeting applications. Invasive bacteria, such as Salmonella, possess the ability to enter and transfer genetic material to human cells, leading to the efficient expression of transferred genes. Attenuated Salmonella strains have earlier been shown to function as a carrier system for delivery of nucleic acid-based vaccines and anti-tumor transgenes. Salmonella-based vectors are low cost and easy to prepare. Furthermore, they can be administrated orally in vivo, a non-invasive delivery route with significant advantage. Thus, Salmonella may represent a promising gene delivery agent for gene therapy. Scientists at UC Berkeley have developed a novel attenuated strain of Salmonella, SL101, which exhibited high gene transfer activity and low cytotoxicity/pathogenicity while efficiently delivering ribozymes, for expression in animals. Using MCMV infection of mice as the model, they demonstrated that oral inoculation of SL101 in animals efficiently delivered RNase P-based ribozyme sequence into specific organs, leading to substantial expression of ribozyme and effective inhibition of viral infection and pathogenesis. This strategy could easily be adopted deliver other gene targeting technologies.

Diagnostic and Screening Methods for Atopic Dermatitis

Atopic dermatitis (AD) is a chronic itch and inflammatory disorder of the skin that affects one in ten people. Patients suffering from severe AD eventually progress to develop asthma and allergic rhinitis, in a process known as the “atopic march.” Signaling between epithelial cells and innate immune cells via the cytokine Thymic Stromal Lymphopoietin (TSLP) is thought to drive AD and the atopic march. TSLP is up regulated in atopic dermatitis patients and is thought to act on immune cells to trigger atopic dermatitis. Scientists at UC Berkeley discovered that TSLP also activates a subset of sensory neurons to signal itch by acting on TSLPR, which signals to TRPA1. They demonstrated that sensory neurons that transmit itch signals in AD are the only instance of signaling between TSLPR and TRPA1 in the same cell type. Therefore, blocking the signaling between TSLPR and TRPA1 is a novel and specific target for therapeutics for itch in atopic dermatitis. They also discovered that the Orai I/Stim I pathway triggers expression and secretion of TSLP. This pathway has never been directly demonstrated in human primary keratinocytes and has never before been linked to TSLP. Decreasing expression of Orai I or stim I using siRNA, or the downstream transcription factor, NFATc I, significantly attenuates TSLP secretion, as proven in mice studies. Thus inhibition of Orai I/Stim I/NFATc I signaling pathway is a novel target for therapeutics for itch in atopic dermatitis.

  • Go to Page:

University of California
Innovation Alliances and Services

1111 Franklin Street, 5th Floor,Oakland,CA 94607-5200 |
http://www.ucop.edu/ott/
Tel: 510.587.6000 | Fax: 510.587.6090 | UC.technologies@ucop.edu